Sunshine vitamin: FANCL data reveals Vitamin D is most popular supplement during
ACI expects healthcare antiseptic manufacturers to lose most active ingredients
The US Food and Drug Administration (FDA) will ban some 80% of active ingredients currently allowed for use in healthcare antiseptics, the American Cleaning Institute (ACI) expects.
Plans to require manufacturers to submit data demonstrating the safety and efficacy of their antibacterial ingredients were set out in a 2015 proposed rule - and are expected to become law when the final rule is issued. The FDA will assess data submitted by industry and decide whether to classify actives as "generally recognised as safe and effective" (Gras/Grae), or ban their use in the products.
ACI expects triclosan to face a ban in healthcare products as well, along with more than 20 other ingredients, its associate vice president for environmental safety, Paul DeLeo, told CW+BiocidesHub.
Some substances will be banned due to a lack of support by industry, he said. "Companies know it won't get FDA approval so they are not willing to do the additional testing the agency is requiring."
Others will fail because the data to support them is too challenging to generate. The agency, he says, is asking for "new methods that we are not aware of anyone having successfully completed in this space", but it has been willing to give companies more time.
You May Interested In
2026-09-20
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Eastman Tritan Products for FANCL Cosmetics Packaging
-
Japanese brewer Kirin plans to acquire Fancl for $1.4 billion
-
Can Addressing Vitamin D Deficiency, Depression, and Diabetes Reduce the Risk of Young-Onset Dementia?
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
Recommend Reading
-
![Chevron Opens Oilfield Chemical Technology to Rivals]()
Chevron Opens Oilfield Chemical Technology to Rivals
-
![Iran Closes Strait of Hormuz to All Vessels: Global Chemical Trade Gets Choked]()
Iran Closes Strait of Hormuz to All Vessels: Global Chemical Trade Gets Choked
-
![China’s Chemical “Spring Surge”: 68.8% of Products Rising—Real Recovery or Just a Pre-Festival Mirage?]()
China’s Chemical “Spring Surge”: 68.8% of Products Rising—Real Recovery or Just a Pre-Festival Mirage?
-
![Stahl Reopens Ranipet Plant]()
Stahl Reopens Ranipet Plant
-
![Sekisui Specialty Chemicals Has Announced a Global Price Increase]()
Sekisui Specialty Chemicals Has Announced a Global Price Increase
-
![Business Society’s MTBE Market Outlook on September 3, 2026: Volatile Consolidation]()
Business Society’s MTBE Market Outlook on September 3, 2026: Volatile Consolidation
-
![Market Support Limited, Coking Coal Market Stabilizes Temporarily in China]()
Market Support Limited, Coking Coal Market Stabilizes Temporarily in China
-
![Business Society’s MTBE Market Outlook on September 2, 2026: Weak Rebound]()
Business Society’s MTBE Market Outlook on September 2, 2026: Weak Rebound
-
![March Hydrogen Peroxide Market Strengthens in China]()
March Hydrogen Peroxide Market Strengthens in China
-
![This Weekend China's Hydrofluoric Acid Market Rises Slightly (7.6-7.10)]()
This Weekend China's Hydrofluoric Acid Market Rises Slightly (7.6-7.10)
